吉林大学学报(医学版) ›› 2024, Vol. 50 ›› Issue (4): 1173-1181.doi: 10.13481/j.1671-587X.20240434
收稿日期:
2022-12-11
出版日期:
2024-07-28
发布日期:
2024-08-01
通讯作者:
李冰,刘国晖
E-mail:libing606419@jlu.edu.cn;liugh@jlu.edu.cn
作者简介:
王晓雨(1997-),女,内蒙古自治区鄂尔多斯市人,在读硕士研究生,主要从事心血管疾病临床和基础方面的研究。
基金资助:
Xiaoyu WANG,Bing LI(),Guohui LIU()
Received:
2022-12-11
Online:
2024-07-28
Published:
2024-08-01
Contact:
Bing LI,Guohui LIU
E-mail:libing606419@jlu.edu.cn;liugh@jlu.edu.cn
摘要:
炎症反应贯穿了冠状动脉粥样硬化性心脏病(CHD)发病和进展的全过程,各种炎症细胞及炎症因子参与其中,并在一定程度上决定着冠状动脉粥样硬化斑块的稳定性和疾病的进展程度。脂蛋白(a)[Lp(a)]、C反应蛋白(CRP)、中性粒细胞、血小板和单核细胞通过诱导炎症因子、刺激炎性细胞和分泌活性物质等多种方式参与炎症反应,发挥促动脉粥样硬化的作用,而淋巴细胞作为重要的免疫细胞,是抗炎的指标。高密度脂蛋白胆固醇(HDL-C)则通过反向运输胆固醇,抑制炎症细胞聚集进而发挥抗动脉粥样硬化的作用。近年来由上述炎症相关指标组合成的新型炎症标志物与CHD的发病及进展关系密切,在CHD的诊断、治疗和预后判断中具有重要的指导意义。降低炎症反应仍是目前CHD研究的热点,现通过分析新型炎症标志物促CHD发展的机制,以及针对相关炎症标志物的治疗进展进行综述,以期为CHD的诊治提供帮助。
中图分类号:
王晓雨,李冰,刘国晖. 炎症标志物在冠状动脉粥样硬化性心脏病诊断和治疗中应用的研究进展[J]. 吉林大学学报(医学版), 2024, 50(4): 1173-1181.
Xiaoyu WANG,Bing LI,Guohui LIU. Research progress in application of inflammatory markers in diagnosis and treatment of coronary heart disease[J]. Journal of Jilin University(Medicine Edition), 2024, 50(4): 1173-1181.
1 | PEÑA-DUQUE M A, ROMERO-IBARRA J L, GAXIOLA-MACÍAS M B, et al. Coronary atherosclerosis and interventional cardiology[J]. Arch Med Res, 2015, 46(5): 372-378. |
2 | KHAN M A, HASHIM M J, MUSTAFA H, et al. Global epidemiology of ischemic heart disease: results from the global burden of disease study[J]. Cureus, 2020, 12(7): e9349. |
3 | DURLACH V, BONNEFONT-ROUSSELOT D, BOCCARA F, et al. Lipoprotein(a): Pathophysiology, measurement, indication and treatment in cardiovascular disease. A consensus statement from the Nouvelle Société Francophone d’Athérosclérose (NSFA)[J]. Arch Cardiovasc Dis, 2021, 114(12): 828-847. |
4 | LAMPSAS S, XENOU M, OIKONOMOU E, et al. Lipoprotein(a) in atherosclerotic diseases: from pathophysiology to diagnosis and treatment[J]. Molecules, 2023, 28(3): 969. |
5 | SHIM Y S, BAEK J W, KANG M J, et al. Reference values for the triglyceride to high-density lipoprotein cholesterol ratio and non-high-density lipoprotein cholesterol in Korean children and adolescents: the Korean national health and nutrition examination surveys 2007-2013[J]. J Atheroscler Thromb, 2016, 23(12): 1334-1344. |
6 | FAN Y, HU J S, GUO F, et al. Lipoprotein(a) as a predictor of poor collateral circulation in patients with chronic stable coronary heart disease[J]. Rev Bras De Pesquisas Med E Biol, 2017, 50(8): e5979. |
7 | HANIF S, AKHTAR B, AFZAL M N. Serum Lipoprotein (a) levels in acute coronary syndrome; Comparison of younger and elderly patients with healthy controls[J]. Pak J Med Sci, 2019, 35(6): 1718-1723. |
8 | KAMSTRUP P R, BENN M, TYBJAERG-HANSEN A, et al. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study[J]. Circulation, 2008, 117(2): 176-184. |
9 | QIN S Y, LIU J, JIANG H X, et al. Association between baseline lipoprotein (a) levels and restenosis after coronary stenting: meta-analysis of 9 cohort studies[J]. Atherosclerosis, 2013, 227(2): 360-366. |
10 | KIMURA T, AKAHORI H, TANAKA T, et al. Impact of lipoprotein (a) on long-term outcome after percutaneous coronary intervention in the era of new generation drug-eluting stents[J]. J Cardiol, 2022, 80(2): 179-183. |
11 | NICHOLLS S J, DITMARSCH M, KASTELEIN J J, et al. Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial[J]. Nat Med, 2022, 28(8): 1672-1678. |
12 | GENCER B, MACH F. Potential of lipoprotein(a)- lowering strategies in treating coronary artery disease[J]. Drugs, 2020, 80(3): 229-239. |
13 | O’DONOGHUE M L, KNUSEL B, et al. Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE)[J]. Am Heart J, 2022, 251: 61-69. |
14 | LAMB Y N. Inclisiran: first approval[J]. Drugs, 2021, 81(3): 389-395. |
15 | MATSUSHITA K, HIBI K, KOMURA N, et al. Impact of serum lipoprotein (a) level on coronary plaque progression and cardiovascular events in statin-treated patients with acute coronary syndrome: a yokohama-acs substudy[J]. J Cardiol, 2020, 76(1): 66-72. |
16 | CESARO A, SCHIAVO A, MOSCARELLA E, et al. Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies[J]. J Cardiovasc Med, 2021, 22(3): 151-161. |
17 | DUARTE LAU F, GIUGLIANO R P. Lipoprotein(a) and its significance in cardiovascular disease: a review[J]. JAMA Cardiol, 2022, 7(7): 760-769. |
18 | REHBERGER LIKOZAR A, ZAVRTANIK M, ŠEBEŠTJEN M. Lipoprotein(a) in atherosclerosis: from pathophysiology to clinical relevance and treatment options[J]. Ann Med, 2020, 52(5): 162-177. |
19 | UELAND T, KLEVELAND O, MICHELSEN A E, et al. Serum lipoprotein(a) is not modified by interleukin-6 receptor antagonism or associated with inflammation in non-ST-elevation myocardial infarction[J]. Int J Cardiol, 2019, 274: 348-350. |
20 | SHEWMON D A, STOCK J L, ROSEN C J, et al. Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women[J]. Arterioscler Thromb, 1994, 14(10): 1586-1593. |
21 | FARZAM K, SENTHILKUMARAN S. Lipoprotein A [M]. Treasure Island (FL): StatPearls Publishing, 2023. |
22 | SAHEBKAR A, SIMENTAL-MENDÍA L E, STEFANUTTI C, et al. Supplementation with coenzyme Q10 reduces plasma lipoprotein(a) concentrations but not other lipid indices: a systematic review and meta-analysis[J]. Pharmacol Res, 2016, 105: 198-209. |
23 | YU C, CHEN M, CHEN Z, et al. Predictive and prognostic value of admission neutrophil-to-lymphocyte ratio in patients with CHD[J]. Herz, 2016, 41(7): 605-613. |
24 | AGARWAL R, AURORA R G, SISWANTO B B, et al. The prognostic value of neutrophil-to-lymphocyte ratio across all stages of coronary artery disease[J]. Coron Artery Dis, 2022, 33(2): 137-143. |
25 | YANG Y, XU Y N, WANG J, et al. Predictive efficacy of neutrophil-to-lymphocyte ratio for long-term prognosis in new onset acute coronary syndrome: a retrospective cohort study[J]. BMC Cardiovasc Disord, 2020, 20(1): 500. |
26 | PAPA A, EMDIN M, PASSINO C, et al. Predictive value of elevated neutrophil-lymphocyte ratio on cardiac mortality in patients with stable coronary artery disease[J]. Clin Chim Acta, 2008, 395(1/2): 27-31. |
27 | TAHTO E, JADRIC R, POJSKIC L, et al. Neutrophil-to-lymphocyte ratio and its relation with markers of inflammation and myocardial necrosis in patients with acute coronary syndrome[J]. Med Arch, 2017, 71(5): 312-315. |
28 | MADJID M, AWAN I, WILLERSON J T, et al. Leukocyte count and coronary heart disease: implications for risk assessment[J]. J Am Coll Cardiol, 2004, 44(10): 1945-1956. |
29 | BOAG S E, DAS R, SHMELEVA E V, et al. T lymphocytes and fractalkine contribute to myocardial ischemia/reperfusion injury in patients[J]. J Clin Invest, 2015, 125(8): 3063-3076. |
30 | KARATAŞ M B, ÇANGA Y, İPEK G, et al. Association of admission serum laboratory parameters with new-onset atrial fibrillation after a primary percutaneous coronary intervention[J]. Coron Artery Dis, 2016, 27(2): 128-134. |
31 | RIDKER P M, EVERETT B M, THUREN T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease[J]. N Engl J Med, 2017, 377(12): 1119-1131. |
32 | ADAMSTEIN N H, CORNEL J H, DAVIDSON M, et al. Association of interleukin 6 inhibition with ziltivekimab and the neutrophil-lymphocyte ratio: a secondary analysis of the RESCUE clinical trial[J]. JAMA Cardiol, 2023, 8(2): 177-181. |
33 | ADAMSTEIN N H, MACFADYEN J G, ROSE L M, et al. The neutrophil-lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials[J]. Eur Heart J, 2021, 42(9): 896-903. |
34 | ADALI M K, BUBER I, KILIC O, et al. Ticagrelor improves systemic immune-inflammation index in acute coronary syndrome patients[J]. Acta Cardiol, 2022, 77(7): 632-638. |
35 | TANI S, MATSUO R, ATSUMI W, et al. Higher frequency of fish intake may be associated with a lower neutrophil/lymphocyte ratio: anti-atherosclerotic effects of fish consumption[J]. Ann Nutr Metab, 2021, 77(3): 146-153. |
36 | AKBAS E M, GUNGOR A, OZCICEK A, et al. Vitamin D and inflammation: evaluation with neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio[J]. Arch Med Sci, 2016, 12(4): 721-727. |
37 | FORDJOUR P A, WANG Y D, SHI Y, et al. Possible mechanisms of C-reactive protein mediated acute myocardial infarction[J]. Eur J Pharmacol, 2015, 760: 72-80. |
38 | OPRESCU N, MICHEU M M, SCAFA-UDRISTE A, et al. Inflammatory markers in acute myocardial infarction and the correlation with the severity of coronary heart disese[J]. Ann Med, 2021, 53(1): 1041-1047. |
39 | LIUZZO G, BIASUCCI L M, GALLIMORE J R, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina[J]. N Engl J Med, 1994, 331(7): 417-424. |
40 | BOHULA E A, GIUGLIANO R P, LEITER L A, et al. Inflammatory and cholesterol risk in the FOURIER trial[J]. Circulation, 2018, 138(2): 131-140. |
41 | SABATINE M S, MORROW D A, DE LEMOS J A, et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide[J]. Circulation, 2002, 105(15): 1760-1763. |
42 | RIDKER P M, CANNON C P, MORROW D, et al. C-reactive protein levels and outcomes after statin therapy[J]. N Engl J Med, 2005, 352(1): 20-28. |
43 | MORROW D A, DE LEMOS J A, SABATINE M S, et al. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial[J]. Circulation, 2006, 114(4): 281-288. |
44 | ZHANG J, WANG X Y, TIAN W D, et al. The effect of various types and doses of statins on C-reactive protein levels in patients with dyslipidemia or coronary heart disease: a systematic review and network meta-analysis[J]. Front Cardiovasc Med, 2022, 9: 936817. |
45 | BALK E M, LAU J, GOUDAS L C, et al. Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review[J]. Ann Intern Med, 2003, 139(8): 670-682. |
46 | NIDORF M, THOMPSON P L. Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease[J]. Am J Cardiol, 2007, 99(6): 805-807. |
47 | AIMO A, PASCUAL FIGAL D A, BAYES-GENIS A, et al. Effect of low-dose colchicine in acute and chronic coronary syndromes: a systematic review and meta-analysis[J]. Eur J Clin Invest, 2021, 51(4): e13464. |
48 | RIDKER P M, DEVALARAJA M, BAERES F M M, et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial[J]. Lancet, 2021, 397(10289): 2060-2069. |
49 | WADA Y, JENSEN C, MEYER A S P, et al. Efficacy and safety of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan (RESCUE-2): a randomized, double-blind, placebo-controlled, phase 2 trial[J]. J Cardiol, 2023, 82(4): 279-285. |
50 | PEPYS M B, HIRSCHFIELD G M, TENNENT G A, et al. Targeting C-reactive protein for the treatment of cardiovascular disease[J]. Nature, 2006, 440(7088): 1217-1221. |
51 | IKONOMIDIS I, ANDREOTTI F, ECONOMOU E, et al. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin[J]. Circulation, 1999, 100(8): 793-798. |
52 | TAKEDA T, HOSHIDA S, NISHINO M, et al. Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels[J]. Atherosclerosis, 2003, 169(1): 155-158. |
53 | TEMIZ A, GAZI E, GUNGOR O, et al. Platelet/lymphocyte ratio and risk of in-hospital mortality in patients with ST-elevated myocardial infarction[J]. Med Sci Monit, 2014, 20: 660-665. |
54 | AKDAG S, AKYOL A, ASKER M, et al. The relation of platelet-lymphocyte ratio and coronary collateral circulation in patients with non-ST segment elevation myocardial infarction[J]. Adv Interv Cardiol, 2016, 12(3): 224-230. |
55 | 石红宾, 李中南, 陈明月, 等. 2型糖尿病合并痛风性关节炎患者单核细胞高密度脂蛋白胆固醇比值与非酒精性脂肪肝关系研究[J]. 中国实用内科杂志, 2024, 44(5): 397-402. |
56 | ZHANG M H, WU S H, XU S, et al. Impact of monocyte to high-density lipoprotein ratio on the identification of prevalent coronary heart disease: insights from a general population[J]. Postgrad Med, 2021, 133(7): 822-829. |
57 | BALTA S, CELIK T, OZTURK C, et al. The relation between monocyte to HDL ratio and no-reflow phenomenon in the patients with acute ST-segment elevation myocardial infarction[J]. Am J Emerg Med, 2016, 34(8): 1542-1547. |
58 | CANPOLAT U, ÇETIN E H, CETIN S, et al. Association of monocyte-to-HDL cholesterol ratio with slow coronary flow is linked to systemic inflammation[J]. Clin Appl Thromb Hemost, 2016, 22(5): 476-482. |
59 | JI H H, LI Y, FAN Z Y, et al. Monocyte/lymphocyte ratio predicts the severity of coronary artery disease: a syntax score assessment[J]. BMC Cardiovasc Disord, 2017, 17(1): 90. |
60 | FAN Z Y, JI H H, LI Y, et al. Relationship between monocyte-to-lymphocyte ratio and coronary plaque vulnerability in patients with stable angina[J]. Biomark Med, 2017, 11(11): 979-990. |
[1] | 黎金连,黄岚珍,黄希仕,李康智,蒋佳丽,张苗苗,吴群英. 肝细胞癌预后、诊断和免疫细胞浸润相关关键基因及其潜在治疗药物的生物信息学分析[J]. 吉林大学学报(医学版), 2024, 50(4): 1062-1075. |
[2] | 曹珊,张艺嘉,白杨,陈芳,谢莎,韩倩倩. 基于消斑通脉方抗动脉粥样硬化作用机制的网络药理学分析和体外实验验证[J]. 吉林大学学报(医学版), 2024, 50(4): 925-938. |
[3] | 冯玉飞,金珊,王玉冰,鲁印飞,庞丽娟,刘克坚. 基于经皮冠状动脉介入治疗术后支架内再狭窄的免疫相关基因及免疫细胞浸润的生物信息学分析[J]. 吉林大学学报(医学版), 2024, 50(3): 749-758. |
[4] | 唐晶,李环,张硕,姜立刚. 急性缺血性脑卒中患者血清中同型半胱氨酸与炎症反应及氧化应激的关联性分析[J]. 吉林大学学报(医学版), 2024, 50(3): 786-790. |
[5] | 于依岩,张志民,陈佳文,刘新,李岩,赵洪岩. 巨噬细胞极化与口腔疾病关系的研究进展[J]. 吉林大学学报(医学版), 2024, 50(3): 864-871. |
[6] | 杨爽,许娜,张剑旭,孙成彪,王燕,董明鑫,刘文森. 甜叶悬钩子苷对脊髓损伤小鼠运动功能障碍和神经炎症的改善作用及其机制[J]. 吉林大学学报(医学版), 2024, 50(2): 326-335. |
[7] | 唐红梅,李月蛟,王星,王志彬,袁谢芳,王孝芸. 桔梗元参汤对过敏性哮喘小鼠气道炎症和黏液分泌的影响及其机制[J]. 吉林大学学报(医学版), 2024, 50(1): 10-17. |
[8] | 刘扬,路明,洪文,黄克林. 姜黄素联合粪菌移植对DSS诱导的小鼠溃疡性结肠炎的改善作用[J]. 吉林大学学报(医学版), 2024, 50(1): 136-142. |
[9] | 于洋,田丹,倪东贺,张铎. 基于罗汉果治疗糖尿病肾病机制的网络药理学和分子对接分析[J]. 吉林大学学报(医学版), 2024, 50(1): 161-167. |
[10] | 葛亚杰,徐文,关诗敏,王丽娜. 多囊卵巢综合征病因及其发病机制的研究进展[J]. 吉林大学学报(医学版), 2024, 50(1): 288-294. |
[11] | 周雪冰,林千千,李艳春. 聚岩藻多糖对小鼠巨噬细胞分泌炎症因子的影响及其机制[J]. 吉林大学学报(医学版), 2023, 49(6): 1452-1456. |
[12] | 李朝政,黄晓巍,张泽鹏,石妍玉,陈颖. 肠-肝轴在动脉粥样硬化发生发展中作用的研究进展[J]. 吉林大学学报(医学版), 2023, 49(6): 1669-1676. |
[13] | 胡志宽,何思琦,蒋维杰,赵贵芳,张佳,齐玲. 脂多糖对小鼠视网膜Müller细胞和小胶质细胞共培养体系中炎症因子水平的影响及其机制[J]. 吉林大学学报(医学版), 2023, 49(5): 1140-1146. |
[14] | 马志楠,张雪竹. 血管性轻度认知障碍的潜在生物标志物研究进展[J]. 吉林大学学报(医学版), 2023, 49(4): 1083-1091. |
[15] | 李海涛, 李沁, 蔡飞, 胡国富, 滕云飞. 芹菜素对小鼠RAW264.7巨噬细胞极化和炎症反应的作用及其机制[J]. 吉林大学学报(医学版), 2023, 49(3): 549-556. |
|